JP2005507897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507897A5 JP2005507897A5 JP2003532038A JP2003532038A JP2005507897A5 JP 2005507897 A5 JP2005507897 A5 JP 2005507897A5 JP 2003532038 A JP2003532038 A JP 2003532038A JP 2003532038 A JP2003532038 A JP 2003532038A JP 2005507897 A5 JP2005507897 A5 JP 2005507897A5
- Authority
- JP
- Japan
- Prior art keywords
- silicon dioxide
- colloidal silicon
- composition
- pharmaceutical composition
- macrolide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 6
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000007884 disintegrant Substances 0.000 claims 4
- 239000007962 solid dispersion Substances 0.000 claims 4
- 239000007919 dispersible tablet Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 claims 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0123400.4A GB0123400D0 (en) | 2001-09-28 | 2001-09-28 | Organic compounds |
| PCT/EP2002/010890 WO2003028705A1 (en) | 2001-09-28 | 2002-09-27 | Pharmaceutical compositions comprising colloidal silicon dioxide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008309431A Division JP5160386B2 (ja) | 2001-09-28 | 2008-12-04 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507897A JP2005507897A (ja) | 2005-03-24 |
| JP2005507897A5 true JP2005507897A5 (OSRAM) | 2005-12-15 |
Family
ID=9922916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532038A Withdrawn JP2005507897A (ja) | 2001-09-28 | 2002-09-27 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
| JP2008309431A Expired - Lifetime JP5160386B2 (ja) | 2001-09-28 | 2008-12-04 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008309431A Expired - Lifetime JP5160386B2 (ja) | 2001-09-28 | 2008-12-04 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20040254210A1 (OSRAM) |
| EP (2) | EP1432408B8 (OSRAM) |
| JP (2) | JP2005507897A (OSRAM) |
| KR (1) | KR100626785B1 (OSRAM) |
| CN (3) | CN1561201A (OSRAM) |
| AR (2) | AR036643A1 (OSRAM) |
| AT (1) | ATE485813T1 (OSRAM) |
| BR (2) | BR0212922A (OSRAM) |
| CA (1) | CA2458455C (OSRAM) |
| CO (1) | CO5390072A1 (OSRAM) |
| CY (2) | CY1111119T1 (OSRAM) |
| DE (1) | DE60238131D1 (OSRAM) |
| DK (2) | DK1432408T3 (OSRAM) |
| EC (1) | ECSP024323A (OSRAM) |
| ES (2) | ES2354687T3 (OSRAM) |
| GB (1) | GB0123400D0 (OSRAM) |
| HU (1) | HU229991B1 (OSRAM) |
| IL (2) | IL160498A0 (OSRAM) |
| MX (1) | MXPA04002814A (OSRAM) |
| MY (1) | MY150060A (OSRAM) |
| NO (1) | NO333892B1 (OSRAM) |
| NZ (2) | NZ531599A (OSRAM) |
| PE (1) | PE20030602A1 (OSRAM) |
| PL (1) | PL209704B1 (OSRAM) |
| PT (2) | PT1432408E (OSRAM) |
| RU (1) | RU2322970C2 (OSRAM) |
| SI (1) | SI1432408T1 (OSRAM) |
| TW (1) | TWI242449B (OSRAM) |
| WO (1) | WO2003028705A1 (OSRAM) |
| ZA (1) | ZA200401300B (OSRAM) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| WO2003064383A2 (en) | 2002-02-01 | 2003-08-07 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds & uses thereof |
| CN100415233C (zh) * | 2002-09-17 | 2008-09-03 | 惠氏公司 | 口服制剂 |
| CA2501556A1 (en) * | 2002-10-09 | 2004-04-29 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for hormone-dependent cancer |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| PL1901773T3 (pl) * | 2005-06-09 | 2012-09-28 | Hansa Medical Ab | Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu |
| CA2669415A1 (en) * | 2006-11-14 | 2008-05-22 | Ariad Pharmaceuticals, Inc. | Solid dosage form comprising ap23573 |
| LT2487163T (lt) | 2007-02-23 | 2016-10-25 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| BRPI0911871A8 (pt) | 2008-05-02 | 2018-03-06 | Gilead Sciences Inc | uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico |
| CN101439025B (zh) * | 2008-12-31 | 2011-05-11 | 江苏大学 | 一种水飞蓟素高效长效制剂及其制法 |
| CN101444503B (zh) * | 2008-12-31 | 2011-02-02 | 江苏大学 | 一种水飞蓟宾高效长效制剂及其制法 |
| CN101444494B (zh) * | 2008-12-31 | 2011-03-30 | 江苏大学 | 难溶性药物高效长效缓释制剂及其制法 |
| US8962036B2 (en) * | 2009-01-21 | 2015-02-24 | Mylan Pharmaceuticals Inc. | Disintegrable formulations of lanthanum carbonate |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| CN102655858B (zh) | 2009-12-22 | 2015-11-25 | Abbvie公司 | Abt-263胶囊 |
| US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| NZ608274A (en) | 2010-10-29 | 2015-05-29 | Abbvie Inc | Solid dispersions containing an apoptosis-inducing agent |
| MY165884A (en) | 2010-11-23 | 2018-05-18 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| SG190361A1 (en) | 2010-11-23 | 2013-06-28 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| DE102011052396A1 (de) * | 2011-08-04 | 2013-02-07 | Gelita Ag | Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung |
| KR101151890B1 (ko) * | 2011-08-11 | 2012-05-31 | 동아제약주식회사 | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 |
| PE20141649A1 (es) | 2011-10-06 | 2014-11-14 | Novartis Ag | Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicina |
| CN102793673A (zh) * | 2012-09-07 | 2012-11-28 | 中国药科大学 | 一种小檗碱磷脂复合物固体分散体及其制备方法 |
| WO2014117035A1 (en) | 2013-01-24 | 2014-07-31 | Transderm, Inc. | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| CA2929181A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
| CN103610646B (zh) * | 2013-12-05 | 2015-07-15 | 江苏奥赛康药业股份有限公司 | 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| WO2016135740A1 (en) | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
| EP3297629A1 (en) | 2015-05-20 | 2018-03-28 | Novartis AG | Pharmaceutical combination of everolimus with dactolisib |
| US10383860B2 (en) | 2015-07-28 | 2019-08-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same |
| EP3466424A1 (en) | 2016-05-27 | 2019-04-10 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprizing rapamycin or derivative thereof |
| CA3038312A1 (en) | 2016-09-30 | 2018-04-05 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
| AU2017363970A1 (en) | 2016-11-23 | 2019-06-20 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
| CA3049402A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| CN110831582B (zh) | 2017-07-05 | 2023-08-11 | 诺华股份有限公司 | 药物组合物 |
| CN108125918B (zh) * | 2018-01-12 | 2020-06-23 | 杭州中美华东制药有限公司 | 依维莫司药物组合物 |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| EP4157221A4 (en) * | 2020-06-01 | 2024-07-24 | Shilpa Medicare Limited | RAPIDLY DISPERSABLE PHARMACEUTICAL COMPOSITION CONTAINING CAPECITABINE |
| WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
| CN119523923A (zh) * | 2024-11-21 | 2025-02-28 | 华中药业股份有限公司 | 一种左炔诺孕酮片及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| US5211958A (en) * | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| US4920102A (en) | 1988-04-18 | 1990-04-24 | Eli Lilly And Company | Method for treating gastrointestinal disorders |
| IT1246383B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
| JP3313710B2 (ja) | 1991-07-03 | 2002-08-12 | ファルマシア・アンド・アップジョン・カンパニー | コレスチポール塩酸塩の錠剤化 |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| IL115742A (en) | 1994-10-26 | 2000-06-01 | Novartis Ag | Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| DE19544507B4 (de) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
| PT890359E (pt) * | 1996-02-29 | 2003-03-31 | Fujisawa Pharmaceutical Co | Comprimidos que contem antibiotico de beta-lactama e processo para a sua preparacao |
| JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
| WO1997040828A1 (fr) * | 1996-04-26 | 1997-11-06 | Shionogi & Co., Ltd. | Comprimes de s1452 a liberation rapide |
| GB2318511A (en) * | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
| CA2271652A1 (en) * | 1996-11-12 | 1998-05-22 | Pharmacia & Upjohn Ab | Compact member comprising a plurality of porous cellulose matrices, (pcms), method of manufacturing and use thereof |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
| TR199903065T2 (xx) | 1997-06-13 | 2000-09-21 | American Home Products Corporation | Oral uygulamaya y�nelik rapamisin form�lasyonlar�. |
| WO1999049863A1 (en) | 1998-03-26 | 1999-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release preparations |
| FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
| GB9826656D0 (en) * | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| EP1161941A4 (en) * | 1999-03-15 | 2002-08-28 | Kaken Pharma Co Ltd | QUICKLY DISMANTLING TABLETS AND METHOD FOR THE PRODUCTION THEREOF |
| FR2793690B1 (fr) | 1999-03-30 | 2003-01-03 | Cll Pharma | Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique |
| BR9917315A (pt) * | 1999-05-21 | 2002-07-30 | Kissei Pharmaceutical | Composições medicinais para liberação imediata para uso oral |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| UA90708C2 (ru) | 2005-02-25 | 2010-05-25 | Ф. Хоффманн-Ля Рош Аг | Таблетки с улучшенной дисперсностью лекарственного вещества |
| TWI358407B (en) | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
-
2001
- 2001-09-28 GB GBGB0123400.4A patent/GB0123400D0/en not_active Ceased
-
2002
- 2002-09-26 EC EC2002004323A patent/ECSP024323A/es unknown
- 2002-09-26 AR ARP020103642A patent/AR036643A1/es not_active Application Discontinuation
- 2002-09-26 PE PE2002000948A patent/PE20030602A1/es not_active Application Discontinuation
- 2002-09-27 AT AT02774661T patent/ATE485813T1/de active
- 2002-09-27 TW TW091122345A patent/TWI242449B/zh not_active IP Right Cessation
- 2002-09-27 HU HU0402394A patent/HU229991B1/hu unknown
- 2002-09-27 EP EP02774661A patent/EP1432408B8/en not_active Expired - Lifetime
- 2002-09-27 DE DE60238131T patent/DE60238131D1/de not_active Expired - Lifetime
- 2002-09-27 NZ NZ531599A patent/NZ531599A/en not_active IP Right Cessation
- 2002-09-27 CA CA2458455A patent/CA2458455C/en not_active Expired - Lifetime
- 2002-09-27 DK DK02774661.9T patent/DK1432408T3/da active
- 2002-09-27 WO PCT/EP2002/010890 patent/WO2003028705A1/en not_active Ceased
- 2002-09-27 PT PT02774661T patent/PT1432408E/pt unknown
- 2002-09-27 MY MYPI20023631A patent/MY150060A/en unknown
- 2002-09-27 ES ES02774661T patent/ES2354687T3/es not_active Expired - Lifetime
- 2002-09-27 RU RU2004113205/15A patent/RU2322970C2/ru active
- 2002-09-27 BR BR0212922-1A patent/BR0212922A/pt not_active IP Right Cessation
- 2002-09-27 DK DK09177889.4T patent/DK2193788T3/en active
- 2002-09-27 PL PL367896A patent/PL209704B1/pl not_active IP Right Cessation
- 2002-09-27 ES ES09177889.4T patent/ES2560106T3/es not_active Expired - Lifetime
- 2002-09-27 US US10/490,089 patent/US20040254210A1/en not_active Abandoned
- 2002-09-27 CN CNA028190459A patent/CN1561201A/zh active Pending
- 2002-09-27 CN CN2010101174089A patent/CN101912392A/zh active Pending
- 2002-09-27 PT PT91778894T patent/PT2193788E/pt unknown
- 2002-09-27 SI SI200230928T patent/SI1432408T1/sl unknown
- 2002-09-27 CO CO02087099A patent/CO5390072A1/es not_active Application Discontinuation
- 2002-09-27 KR KR1020047004628A patent/KR100626785B1/ko not_active Expired - Lifetime
- 2002-09-27 NZ NZ542273A patent/NZ542273A/en not_active IP Right Cessation
- 2002-09-27 IL IL16049802A patent/IL160498A0/xx unknown
- 2002-09-27 BR BRPI0212922-1A patent/BRPI0212922B1/pt unknown
- 2002-09-27 JP JP2003532038A patent/JP2005507897A/ja not_active Withdrawn
- 2002-09-27 EP EP09177889.4A patent/EP2193788B1/en not_active Expired - Lifetime
- 2002-09-27 MX MXPA04002814A patent/MXPA04002814A/es active IP Right Grant
- 2002-09-27 CN CN2006101159063A patent/CN1951390B/zh not_active Expired - Lifetime
-
2004
- 2004-02-18 ZA ZA200401300A patent/ZA200401300B/en unknown
- 2004-02-19 IL IL160498A patent/IL160498A/en active IP Right Grant
- 2004-03-26 NO NO20041270A patent/NO333892B1/no not_active IP Right Cessation
-
2008
- 2008-12-04 JP JP2008309431A patent/JP5160386B2/ja not_active Expired - Lifetime
-
2010
- 2010-05-10 US US12/776,711 patent/US20100221331A1/en not_active Abandoned
- 2010-11-30 CY CY20101101091T patent/CY1111119T1/el unknown
-
2011
- 2011-06-13 US US13/158,921 patent/US20110306630A1/en not_active Abandoned
-
2012
- 2012-06-05 US US13/489,396 patent/US8617598B2/en not_active Expired - Lifetime
-
2014
- 2014-08-14 AR ARP140103055A patent/AR097341A2/es unknown
-
2016
- 2016-01-21 CY CY20161100068T patent/CY1117164T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507897A5 (OSRAM) | ||
| JP2009102341A5 (OSRAM) | ||
| CA2458455A1 (en) | Pharmaceutical compositions comprising colloidal silicon dioxide | |
| TWI254640B (en) | Use of a polymer of acrylic type as a disintegration agent | |
| US20200078354A1 (en) | Immediate release abuse deterrent tablet | |
| JP6067100B2 (ja) | 即放性乱用抑止医薬組成物 | |
| WO2004064752A3 (en) | Method of preparing sustained release microparticles | |
| JP5750847B2 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
| WO2004100857A3 (en) | Highly plastic granules for making fast melting tablets | |
| JP2006527184A5 (OSRAM) | ||
| WO2009043844A3 (en) | Orodispersible tablets | |
| JP2010518086A5 (OSRAM) | ||
| TW200635618A (en) | Solid dosage form comprising proton pump inhibitor and suspension made thereof | |
| JPWO2009151072A1 (ja) | 口腔内速崩壊錠及びその製造方法 | |
| WO2007071581A3 (de) | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten | |
| WO2003047552A3 (en) | Pharmaceutical composition comprising a 5ht1 receptor agonist | |
| HRP20100120T1 (hr) | Formulacije s valsartanom | |
| JP2014530802A5 (OSRAM) | ||
| CA2502731A1 (en) | Sustained release composition for oral administration of drugs | |
| JP2011516544A5 (OSRAM) | ||
| GEP20125636B (en) | Slow-release formulation based on glycogen and alginate association | |
| UA87515C2 (ru) | Фармацевтическая композиция толтеродина с пролонгированным высвобождением | |
| EA201001108A1 (ru) | Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения | |
| JP2019014666A5 (OSRAM) | ||
| JP2002537246A5 (OSRAM) |